Market Overview

OncoSec Medical Announces Positive Interim Data from Phase 2 Metastatic Melanoma Study

OncoSec Medical (OTC: ONCS) today announced positive interim data from its ongoing Phase 2
trial of OMS-I100 in the treatment of metastatic melanoma. The results
were presented by principal…
OncoSec Medical (OTC: ONCS today announced positive interim data from its ongoing Phase 2
trial of OMS-I100 in the treatment of metastatic melanoma. The results
were presented by principal investigator Adil Daud, MD, at the Advances
in Cancer Immunotherapy meeting at the University of California San
Francisco.

Data from the multicenter, open-label, single-arm study confirm the
safety of OncoSec's lead product candidate, ImmunoPulse, which leverages
the company's OMS electroporation technology to deliver the anti-tumor
agent pIL-12 directly into the tumor. In Phase 1 and Phase 2 studies, a
total of 47 melanoma patients have been treated to date without a single

See full press release

Posted-In: News Guidance Financing Management Global

 

Most Popular

Related Articles (ONCS)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free